Webinar "Management of Hemophilia as a Rare Disease: Models for Accessing Innovative Therapies" Türkiye

We continue our series of webinars on MCDA in the field of rare diseases!

On December 2nd at 4:00 PM (Moscow time), the next online webinar will be held by our colleagues from Turkey. The webinar will be in English.

The meeting will discuss modern approaches to the evaluation of innovative hemophilia therapies based on the principles of multicriteria decision analysis (MCDA).

Why is this important?

In Turkey, as in many countries, hemophilia remains one of the most costly diseases. Today, clinicians have a wide range of innovative drugs at their disposal, making the following particularly important:

• informed therapy selection,

• accurate assessment of its value,

• definition of the therapeutic niche,

• modern approaches to procurement and access.

During the webinar, experts will present the current situation with drug provision for patients in Turkey and share the development of new tools for assessing hemophilia therapy based on MCDA.

Webinar Topic:

Managing Hemophilia as a Rare Disease: Models for Evaluating Innovative Therapies

Speakers:

• Prof. Dr. Zafer Çalışkan — Hacettepe University, Head of Department of Economics; Vice Director of Vaccine Institute

• Esra Şafak Yılmaz, PhD – Healthcare Policy Manager, Novo Nordisk

• Kağan Atikeler, Pharm. – Market Access Lead, Sanofi

We remind you: the first webinar of the series took place on October 22. The recording is available on the CIS Orphan Consortium website (https://orphan-cis.net/events/351/)

Join the international discussion of modern orphan technology assessment tools!